Imipenem combined with BLI-489 had a synergistic effect on 7/10, 7/9 and 5/6 of carbapenem-resistant K. Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae.
| Excerpt | Reference | Relevance |
|---|
| "The in vivo efficacy of piperacillin in combination with the penem inhibitor BLI-489 was determined using acute lethal systemic infections in mice." | ( Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection.
Bradford, PA; Jones, CH; Petersen, PJ; Venkatesan, AM, 2009) | 0.35 |
| "In the present study, the in vitro and in vivo activities of imipenem combined with BLI-489 against CRAb producing carbapenem-hydrolysing class D β-lactamases (CHDLs), namely OXA-23, OXA-24, OXA-51 and OXA-58, were determined." | ( In vitro and in vivo activities of imipenem combined with BLI-489 against class D β-lactamase-producing Acinetobacter baumannii.
Chen, TL; Chiang, MH; Chiu, CH; Huang, SW; Kuo, SC; Lee, IM; Lee, YT; Su, YS; Wang, FD; Wang, YC; Yang, YS, 2021) | 0.62 |
| "Imipenem combined with BLI-489 has synergistic effects against CHDL-producing CRAb isolates." | ( In vitro and in vivo activities of imipenem combined with BLI-489 against class D β-lactamase-producing Acinetobacter baumannii.
Chen, TL; Chiang, MH; Chiu, CH; Huang, SW; Kuo, SC; Lee, IM; Lee, YT; Su, YS; Wang, FD; Wang, YC; Yang, YS, 2021) | 0.62 |
| "To investigate the antibacterial activity of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales (CRE) in vivo and in vitro." | ( Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.
Liu, Q; Shi, S; Xu, M; Yao, Z; Ye, J; Zhang, X; Zhang, Y; Zhou, B; Zhou, C; Zhou, T, 2022) | 0.72 |
| "Twenty-five CRE strains, including Klebsiella pneumoniae (n = 10), Escherichia coli (n = 6) and Enterobacter cloacae (n = 9), were used in chequerboard assays to evaluate the synergistic effect of BLI-489 combined with imipenem or meropenem." | ( Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.
Liu, Q; Shi, S; Xu, M; Yao, Z; Ye, J; Zhang, X; Zhang, Y; Zhou, B; Zhou, C; Zhou, T, 2022) | 0.72 |
| "The novel β-lactamase inhibitor BLI-489 possesses a synergistic effect against diverse carbapenemase-producing CRE combined with imipenem or meropenem." | ( Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.
Liu, Q; Shi, S; Xu, M; Yao, Z; Ye, J; Zhang, X; Zhang, Y; Zhou, B; Zhou, C; Zhou, T, 2022) | 0.72 |